Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer

Documenti analoghi

• Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
  di: Guo, Yijia, et al.
  Pubblicazione: (2020)
• Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations
  di: Zhang, Minghui, et al.
  Pubblicazione: (2016)
• Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
  di: Han, Ruoshuang, et al.
  Pubblicazione: (2021)
• Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
  di: Holleman, Marscha S., et al.
  Pubblicazione: (2019)
• Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
  di: Fang Wang, et al.
  Pubblicazione: (2019-03-01)